Shares of Eli Lilly soared Thursday morning after the pharmaceutical giant announced a clinical trial of its once-daily ...

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

Mounjaro, manufactured by Lilly, may have emerged as the newest and most effective treatment option after a victory over Novo Nordisk’s Ozempic in clinical trials. For some patients, injectables ...

One of the highlights of Eli Lilly's third-quarter results was the rapid uptake of new type 2 diabetes therapy Mounjaro, which added more than $97 million in US sales alone in what has been ...

As it stands today, Mounjaro is Lilly's largest source of revenue while ... through the nine-month period April through December 2024. To add some color to these figures, Eisai actually revised ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and Mounjaro.

Claim your 7-day free trial now. Eli Lilly & Co. LLY shares are trading higher Thursday after the company launched its weight-loss drug Mounjaro in India. What To Know: According to Reuters ...

Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, approved by CDSCO, helps with weight management and activates hormone receptors.

Eli Lilly is suing two pharmacies for compounding Zepbound and Mounjaro, claiming the companies are skirting the Food and Drug Administration's ban on the practice and luring people away from ...